title: Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor.
abstract: Five syngeneic transplants were performed in four patients following myeloablative therapy using unmodified peripheral blood mononuclear cells (PBMCs) collected after the administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) to normal donors. The only toxicity experienced by the four normal donors was bone pain. Four patients received two collections of PBMCs, and a second transplant was performed in one patient with one collection. The patients received a median of 20.53 x 10(8) total nucleated cells/kg (range 20 to 25.5), 11.3 x 10(8) total mononuclear cells/kg (range 6.52 to 17.2), 113.1 x 10(4)/kg CFU-GM (range 46.7 to 211.8) and 9.6 x 10(6) CD34+ cells/kg (range 1.6 to 12.6) Post-transplant growth factors were not administered. The median time to an absolute neutrophil count greater than 0.5 x 10(9)/L was 14 days (range 10 to 18). The median time to platelet transfusion independence was 11 days (range 10 to 13). Two patients had the number of CD3+ T lymphocytes determined in the pheresis product. An average of 3.04 x 10(10) CD3+ cells were collected per pheresis. This represents an approximate 1 log increase over the number of T lymphocytes in a typical bone marrow transplant. Rh-GCSF can be used to mobilize peripheral blood progenitor cells from normal donors with minimal toxicity. Studies of allogeneic transplants using PBMCs collected after rhG-CSF administration to determine permanent grafting ability and the incidence and severity of graft-versus-host disease are warranted.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
authors.forename: C H
authors.initials: CH
authors.lastname: Weaver
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: K
authors.initials: K
authors.lastname: Longin
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: S
authors.initials: S
authors.lastname: Rowley
authors.forename: K
authors.initials: K
authors.lastname: Lilleby
authors.forename: J
authors.initials: J
authors.lastname: Miser
authors.forename: R
authors.initials: R
authors.lastname: Storb
authors.forename: J A
authors.initials: JA
authors.lastname: Hansen
authors.forename: W
authors.initials: W
authors.lastname: Bensinger
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34; D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007937:Leukapheresis; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000637:transplantation*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012512:Sarcoma, Ewing / Q000628:therapy*; D014185:Transplantation, Isogeneic
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor